Abstract:To fully explore the clinical possibility of honokiol, we encapsulated honokiol with long circulating liposome to improve its solubility and prolong its circulation time in body. The potential to increase the antitumor effect of liposomal honokiol by combination with cisplatin and possible mechanism have been investigated in in vitro and in vivo. Honokiol was encapsulated with long circulating modified liposomes. The pharmacokinetic study and biodistribution of liposomal honokiol in tumor-bearing mice was detected by high performance liquid chromatography. Inhibition of cell proliferation and induction of apoptosis by liposomal honokiol were tested in vitro. In in vivo study, LL/2 tumor model and human A549 tumor models were established in C57BL/6N mice and athymic nude mice, respectively. Mice were treated with PBS group, liposomal honokiol, free liposome, cisplatin, and liposomal honokiol plus cisplatin. Tumor volume and survival time were observed and the mechanisms underlying the anti-tumor effect was investigated by detecting the microvessel density, apoptosis in tumor tissue. Liposomal honokiol has shown remarkable improvement of water solubility and could be dissolved in PBS for i.p injection. The improvement of bioavailability of honokiol, sustained release of honokiol and prolongation of half-time were obtained. The inhibition of cell proliferation and induced apoptosis of liposomal honokiol were time and dose-dependent in in vitro study. The liposomal honokiol inhitbited tumor growth in a dose-dependent manner and the antitumor efficacy of liposomal honokiol can be significantly enhanced in combination with cisplatin. This combination treatment has shown marked suppression in tumor growth, prolonged survival and decreased microvessel density compared with either treatment alone. The in vitro and in vivo antitumor effects of liposomal honokiol combined with cisplatin indicated that liposomal honokiol can be a potential agent as a new sensitizer of anti- lung cancer drug.

Preparation of honokiol with biodegradable nanoparticles for treatment of osteosarcoma

Honokiol Induces Apoptosis and Autophagy Via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo.

Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro.

Synthesis, Structural and in Vitro Studies of Well-Dispersed Monomethoxy-Poly(Ethylene Glycol)-Honokiol Conjugate Micelles

Honokiol-loaded PLGA-PEG nanoparticles with solubility in water for infusion treatment of solid cancer

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite

Preparation of honokiol nanoparticles by liquid antisolvent precipitation technique, characterization, pharmacokinetics, and evaluation of inhibitory effect on HepG2 cells

Enhancing the Anti-Glioma Therapy of Doxorubicin by Honokiol with Biodegradable Self-Assembling Micelles Through Multiple Evaluations.

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Anti-tumor efficacies of liposomal honokiol combined with cisplatin in lewis lung cancer and human a 549 lung cancer models: P3-027

Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization.

Liposomal Honokiol, a Potent Anti-Angiogenesis Agent, in Combination with Radiotherapy Produces a Synergistic Antitumor Efficacy Without Increasing Toxicity.

A Novel Honokiol Liposome: Formulation, Pharmacokinetics, and Antitumor Studies.

Synergistic Antitumor Effects of Liposomal Honokiol Combined with Adriamycin in Breast Cancer Models.

Tumor Microenvironment-Responsive Hyaluronate-Calcium Carbonate Hybrid Nanoparticle Enables Effective Chemotherapy for Primary and Advanced Osteosarcomas

Self-assembled Hydrophobic Honokiol Loaded MPEG-PCL Diblock Copolymer Micelles.

Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Honokiol: a Promising Small Molecular Weight Natural Agent for the Growth Inhibition of Oral Squamous Cell Carcinoma Cells.

PLK1shRNA and Doxorubicin Co-Loaded Thermosensitive PLGA-PEG-PLGA Hydrogels for Osteosarcoma Treatment

Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion.